-
Uddannelse
Find uddannelse
Studievejledning
Besøg AU
Kvalitet
-
Forskning
Aktuel forskning
Talent
-
Samarbejde
Gymnasier
Myndigheder
Alumner
- Om AU
Mads Fuglsang Kjølby is part of an international team of researchers around Markus Hoffmann and Stefan Pöhlmann from the German Primate Center (DPZ) – Leibniz Institute for Primate Research, and has now shown that SARS-CoV-2 can use several TMPRSS2-related proteases for its activation.
09.03.2021
There are no therapeutics available that have been developed for COVID-19 treatment. Repurposing of already available medication for COVID-19 therapy is an attractive option to shorten the road to treatment development. The drug Camostat could be suitable. Camostat exerts antiviral activity by blocking the protease TMPRSS2, which is used by SARS-CoV-2 for entry into cells. However, it was previously unknown whether SARS-CoV-2 can use TMPRSS2-related proteases for cell entry and whether these proteases can be blocked by Camostat. Moreover, it was unclear whether metabolization of Camostat interferes with antiviral activity.
Mads Fuglsang Kjølby is part of an international team of researchers around Markus Hoffmann and Stefan Pöhlmann from the German Primate Center (DPZ) – Leibniz Institute for Primate Research, and has now shown that SARS-CoV-2 can use several TMPRSS2-related proteases for its activation.
These proteases are expressed in the upper respiratory tract and are blocked by Camostat. In addition, the researchers found that Camostat and its major metabolite GBPA inhibit SARS-CoV-2 infection of primary human lung tissue.
These findings support the further development of Camostat and related compounds for COVID-19 therapy (EBioMedicine).
Original publication
Hoffmann, M et al. (2021). Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-
related proteases and its metabolite GBPA exerts antiviral activity. EBioMedicine, DOI:
10.1016/j.ebiom.2021.103255
www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00048-7/fulltext